145 related articles for article (PubMed ID: 34764094)
41. Effect of sustained-release long-acting intravitreal dexamethasone implant in patients of non-proliferative diabetic retinopathy undergoing phacoemulsification: A randomized controlled trial.
Gupta PC; Ram J; Kumar MP; Agarwal A; Gupta V; Singh R; Bansal R; Katoch D; Dogra MR; Gupta A
Indian J Ophthalmol; 2021 Nov; 69(11):3263-3272. PubMed ID: 34708785
[TBL] [Abstract][Full Text] [Related]
42. Unilateral intravitreal dexamethasone implant for diabetic macular edema: effect in the contralateral eye.
Pareja-Ríos A; Bonaque-González S
Arq Bras Oftalmol; 2020; 83(1):73-75. PubMed ID: 31691729
[TBL] [Abstract][Full Text] [Related]
43. CASE REPORT OF ABIOTROPHIA DEFECTIVA ENDOPHTHALMITIS AFTER REPEATED INJECTIONS OF DEXAMETHASONE INTRAVITREAL IMPLANT (OZURDEX).
Cruz-Iñigo YJ; Klein K; Reddy RK
Retin Cases Brief Rep; 2022 Mar; 16(2):170-173. PubMed ID: 31479011
[TBL] [Abstract][Full Text] [Related]
44. Intravitreal Injection of Sulfamethoxazole and Trimethoprim Associated with Dexamethasone as an Alternative Therapy for Ocular Toxoplasmosis.
Souza CE; Nascimento H; Lima A; Muccioli C; Belfort R
Ocul Immunol Inflamm; 2018; 26(7):1041-1044. PubMed ID: 28448726
[TBL] [Abstract][Full Text] [Related]
45. Comparison of the Safety and Efficacy of Intravitreal Ranibizumab with or without Laser Photocoagulation Versus Dexamethasone Intravitreal Implant with or without Laser Photocoagulation for Macular Edema Secondary to Branch Retinal Vein Occlusion.
Kumar P; Sharma YR; Chandra P; Azad R; Meshram GG
Folia Med (Plovdiv); 2019 Jun; 61(2):240-248. PubMed ID: 31301668
[TBL] [Abstract][Full Text] [Related]
46. A review of ten years of experience using dexamethasone intravitreal implants (Ozurdex) for uveitis.
Zeng S; Liu XL
Eur Rev Med Pharmacol Sci; 2023 Mar; 27(5):1743-1758. PubMed ID: 36930471
[TBL] [Abstract][Full Text] [Related]
47. Rebound effect after intravitreal dexamethasone implant for the treatment of macular edema secondary to central retinal vein occlusion.
Parodi MB; Iacono P; De Benedetto U; Cascavilla M; Bandello F
J Ocul Pharmacol Ther; 2012 Dec; 28(6):566-8. PubMed ID: 22746671
[TBL] [Abstract][Full Text] [Related]
48. Intravitreal triamcinolone acetonide versus combined intravitreal bevacizumab and dexamethasone in diffuse diabetic macular oedema.
Sheth S; Rush R; Natarajan S; Gillies M
Clin Exp Ophthalmol; 2011; 39(7):673-81. PubMed ID: 22452685
[TBL] [Abstract][Full Text] [Related]
49. Cancer-associated retinopathy preceding the diagnosis of cancer.
Hoogewoud F; Butori P; Blanche P; Brézin AP
BMC Ophthalmol; 2018 Nov; 18(1):285. PubMed ID: 30390655
[TBL] [Abstract][Full Text] [Related]
50. Intravitreal dexamethasone 0.7-mg implant for radiation macular edema after proton beam therapy for choroidal melanoma.
Baillif S; Maschi C; Gastaud P; Caujolle JP
Retina; 2013 Oct; 33(9):1784-90. PubMed ID: 23652581
[TBL] [Abstract][Full Text] [Related]
51. Intravitreal dexamethasone implants versus intravitreal anti-VEGF treatment in treating patients with retinal vein occlusion: a meta-analysis.
Gao L; Zhou L; Tian C; Li N; Shao W; Peng X; Shi Q
BMC Ophthalmol; 2019 Jan; 19(1):8. PubMed ID: 30621640
[TBL] [Abstract][Full Text] [Related]
52. Effect of dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes of Taiwanese patients with treatment-naïve diabetic macular edema.
Wang JK; Huang TL; Chang PY
J Formos Med Assoc; 2020 Nov; 119(11):1619-1625. PubMed ID: 32482606
[TBL] [Abstract][Full Text] [Related]
53. Dexamethasone Intravitreal Implant for Chronic Diabetic Macular Edema Resistant to Intravitreal Bevacizumab Treatment.
Totan Y; Güler E; Gürağaç FB
Curr Eye Res; 2016; 41(1):107-13. PubMed ID: 25610946
[TBL] [Abstract][Full Text] [Related]
54. Use of intravitreal dexamethasone implants in the treatment of diabetic macular edema: Expert recommendations using a Delphi approach.
García Layana A; Adán A; Ascaso FJ; Cabrera F; Donate J; Escobar Barranco JJ; Peralta G; Reyes García R; Rodríguez Maqueda M; Ruiz-Moreno JM; Vinagre I;
Eur J Ophthalmol; 2020 Sep; 30(5):1042-1052. PubMed ID: 31291782
[TBL] [Abstract][Full Text] [Related]
55. [Early efficacy of dexamethasone implant (OZURDEX
Sarda V; Fajnkuchen F; Nghiem-Buffet S; Grenet T; Chaine G; Giocanti-Auregan A
J Fr Ophtalmol; 2017 May; 40(5):408-413. PubMed ID: 28336283
[TBL] [Abstract][Full Text] [Related]
56. Treatment of Non-infectious Uveitic Macular Edema with the Intravitreal Dexamethasone Implant.
Nobre-Cardoso J; Champion E; Darugar A; Fel A; Lehoang P; Bodaghi B
Ocul Immunol Inflamm; 2017 Aug; 25(4):447-454. PubMed ID: 27003221
[TBL] [Abstract][Full Text] [Related]
57. [Tolerability and short-term efficacy of the Ozurdex® dexamethasone intravitreal implant for treatment of uveitic cystoid macular edema: A retrospective study of 52 injections performed at the Clermont-Ferrand teaching hospital].
Bernard Y; Bonnin N; Farguette F; Chiambaretta F
J Fr Ophtalmol; 2016 Jan; 39(1):1-4. PubMed ID: 26616298
[TBL] [Abstract][Full Text] [Related]
58. [Treatment of postoperative cystoid macular edema (Irvine-Gass syndrome) with dexamethasone 0.7 mg intravitreal implant].
Landré C; Zourdani A; Gastaud P; Baillif S
J Fr Ophtalmol; 2016 Jan; 39(1):5-11. PubMed ID: 26520410
[TBL] [Abstract][Full Text] [Related]
59. Comparison between "early" or "late" intravitreal injection of dexamethasone implant in branch (BRVO) or central (CRVO) retinal vein occlusion: six-months follow-up.
Pacella F; La Torre G; Basili S; Autolitano M; Pascarella A; Lenzi T; Pacella E
Cutan Ocul Toxicol; 2017 Sep; 36(3):224-230. PubMed ID: 27903073
[TBL] [Abstract][Full Text] [Related]
60. Use of intravitreal dexamethasone implant in patients with cataract and macular edema undergoing phacoemulsification.
Sze AM; Luk FO; Yip TP; Lee GK; Chan CK
Eur J Ophthalmol; 2015; 25(2):168-72. PubMed ID: 25363857
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
